Skip to main content
Premium Trial:

Request an Annual Quote

Pattern Recognition Mass Spec Mania


GenomeWeb’s latest market research report looks at protein mass-spec technology to figure out what users think of certain instruments and software and how they’re using those in their research. We’ve included a few of the graphs below — find out what your peers are up to and see how your research and results compare to theirs.

Survey respondents told us that protein identification takes up the biggest chunk of their time now, but that in the future they expect that to drop significantly in order for differential proteomics to get more attention.


Not surprisingly, the last couple of years have been tough on scientists’ purse-strings. According to respondents, more than a quarter spent absolutely no money on mass spec equipment during the last two years. The outlook’s a little brighter: though again more than 25 percent expect to spend no money, nearly half of all respondents predict they will spend up to half a million dollars on new equipment.


NHGRI: Show Us the Money


Late last year NHGRI formally announced the establishment of its Large-Scale Sequencing Research Network — but what everyone really wanted to know was which genome centers got how many bucks. The five major centers that applied (the HGP Big Three as well as Venter’s foundation and Agencourt Bioscience) were collectively awarded $163 million for fiscal year ’04, with the same amount planned for 2005 and a drop to $133 million in 2006. That ought to translate to some 54 billion base pairs — or 18 human genomes — over three years.


For 2004, here’s how the grants shook out:
Eric Lander, Broad Institute: $59 M
Rick Wilson, Washington University: $49 M
Richard Gibbs, Baylor: $35 M
Doug Smith, Agencourt Bioscience: $10 M
Craig Venter, TIGR: $10 M


The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.